Cultural Foundation
Author:
OSE Immunotherapeutics
OSE Immunotherapeutics to Present a Novel, First-in-Class, FPR2 Agonist Monoclonal Antibody in the Resolution of Chronic Inflammation at the AAI 2026 Meeting
April 15, 2026
OSE Immunotherapeutics Evolves its Leadership Team
April 14, 2026
OSE Immunotherapeutics Confirms Marc Le Bozec as Chief Executive Officer to Lead Next Phase of Strategic Growth
March 10, 2026